Organon Seeks FDA Nod to Extend Miudella IUD Use to Six Years — Organon & Co.

Event summary

FDA accepted Organon’s supplemental New Drug Application (sNDA) for Miudella, a hormone-free IUD, seeking approval for extended use up to six years.
Organon licensed global rights to Miudella from Sebela Women’s Health in June 2026.
Miudella is currently approved for up to three years of use and is anticipated to be commercially available in late 2026.
The FDA’s decision is expected in Q2 2027 under the Prescription Drug User Fee Act (PDUFA).
Miudella’s clinical trials involved 1,904 women and demonstrated 99% efficacy over three years.

The big picture

Organon’s push to extend Miudella’s approval reflects a broader industry trend toward longer-lasting, hormone-free contraceptive options. The move aligns with increasing demand for non-hormonal birth control methods, particularly among women seeking extended efficacy without hormonal side effects. The success of this application could position Organon as a key player in the women’s health sector, leveraging its existing portfolio of over 70 products.

What we're watching

Regulatory Approval: Whether the FDA will approve the extended use of Miudella by Q2 2027, which would significantly expand its market potential.
Market Competition: How Organon will position Miudella against existing hormone-free IUDs in a competitive contraception market.
Commercialization Strategy: The pace at which Organon can scale Miudella’s commercial availability post-approval, given the REMS requirements for healthcare provider training.